Literature DB >> 31005902

Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre.

Hanxiao You1, Guizhi Zhang2, Qian Wang1, Shangzhu Zhang1, Jiuliang Zhao1, Xinping Tian1, Hongbin Li2, Mengtao Li3, Xiaofeng Zeng3.   

Abstract

Entities:  

Keywords:  arthritis; janus kinase; rash; systemic lupus erythematosus; treatment

Mesh：

Substances：

Year:  2019        PMID： 31005902     DOI： 10.1136/annrheumdis-2019-215455

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  12 in total

1.  Refractory dermatomyositis-systemic lupus erythematosus overlap syndrome and response to tofacitinib.

Authors:  Preston Williams; Benjamin McKinney
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-09-28

Review 2.  JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.

Authors:  Yiming Luo; Madison Alexander; Massimo Gadina; John J O'Shea; Francoise Meylan; Daniella M Schwartz
Journal:  J Allergy Clin Immunol       Date:  2021-10       Impact factor: 14.290

3.  Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib.

Authors:  Yu-Lan Chen; Li-Xiong Liu; Qin Huang; Xue-Ying Li; Xiao-Ping Hong; Dong-Zhou Liu
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

Review 4.  Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus.

Authors:  Przemysław Kotyla; Olga Gumkowska-Sroka; Bartosz Wnuk; Kacper Kotyla
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-28

Review 5.  Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?

Authors:  Patricia Richter; Anca Cardoneanu; Alexandra Maria Burlui; Luana Andreea Macovei; Ioana Bratoiu; Oana Nicoleta Buliga-Finis; Elena Rezus
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

6.  Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

Authors:  Sarfaraz A Hasni; Sarthak Gupta; Michael Davis; Elaine Poncio; Yenealem Temesgen-Oyelakin; Philip M Carlucci; Xinghao Wang; Mohammad Naqi; Martin P Playford; Rishi R Goel; Xiaobai Li; Ann J Biehl; Isabel Ochoa-Navas; Zerai Manna; Yinghui Shi; Donald Thomas; Jinguo Chen; Angélique Biancotto; Richard Apps; Foo Cheung; Yuri Kotliarov; Ashley L Babyak; Huizhi Zhou; Rongye Shi; Katie Stagliano; Wanxia Li Tsai; Laura Vian; Nathalia Gazaniga; Valentina Giudice; Shajia Lu; Stephen R Brooks; Meggan MacKay; Peter Gregersen; Nehal N Mehta; Alan T Remaley; Betty Diamond; John J O'Shea; Massimo Gadina; Mariana J Kaplan
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

Review 7.  New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond.

Authors:  Erkan Demirkaya; Sezgin Sahin; Micol Romano; Qing Zhou; Ivona Aksentijevich
Journal:  J Clin Med       Date:  2020-03-05       Impact factor: 4.241

Review 8.  New developments in systemic lupus erythematosus.

Authors:  Michel W P Tsang-A-Sjoe; Irene E M Bultink
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

9.  Oral tofacitinib citrate for recalcitrant cutaneous lupus.

Authors:  Evelyne Bonnardeaux; Jan P Dutz
Journal:  JAAD Case Rep       Date:  2021-10-02

10.  Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound.

Authors:  Rositsa Valerieva Karalilova; Zguro Anastasov Batalov; Tanya Lyubomirova Sapundzhieva; Marco Matucci-Cerinic; Anastas Zgurov Batalov
Journal:  Rheumatol Int       Date:  2021-07-27       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.